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Embryonal rhabdomyosarcoma (eRMS) is one of themost common soft tissue sarcomas in children and adolescents. Parameningeal
eRMS is a variant that is often more difficult to treat than eRMS occurring at other sites. A 14-year-old female with persistent
headaches and rapid weight loss was diagnosed with parameningeal eRMS. She progressed and died despite chemotherapy with
vincristine, actinomycin-D, and cyclophosphamide plus 50.4Gy radiation therapy to the primary tumor site. Tumor specimens
were acquired by rapid autopsy and tumor tissue was transplanted into immunodeficient mice to create a patient-derived xenograft
(PDX) animal model. As autopsy specimens had an ALK R1181C mutation, PDX tumor bearing animals were treated with the pan-
kinase inhibitor lestaurtinib but demonstrated no decrease in tumor growth, suggesting that single agent kinase inhibitor therapy
may be insufficient in similar cases. This unique parameningeal eRMS PDX model is publicly available for preclinical study.
1. Introduction
Rhabdomyosarcomas (RMS) aremesenchymal tumors show-
ing skeletal muscle differentiation and represent the most
common pediatric soft tissue sarcomas [1]. RMS are subdi-
vided into alveolar (aRMS) and embryonal (eRMS) types,
with each category showing distinct histologic appearance,
behavior, and response to treatment. Approximately, 60% of
RMS are the embryonal type [2]. eRMS presents commonly
in the genitourinary and head and neck regions. Compared to
aRMS, the average age of onset of embryonal rhabdomyosar-
coma is younger, with a majority of cases diagnosed before
age 10, and the prognosis is overall more favorable [3]. While
the majority of aRMS show balanced translocation with
fusion of PAX3:FOX01 or PAX7:FOX01, recent publications
suggest that driver mutations (e.g., NRAS, KRAS, HRAS,
FGFR4, PIK3CA, CTNNB1, FBXW7, and BCOR) may under-
pin progression in the embryonal subtype of RMS (eRMS) [4,
5]. These studies have suggested that translocation negative
aRMS may be more similar to eRMS than the histologic
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appearance might suggest [6, 7]. eRMS as currently defined
overall shows a better prognosis than aRMS with 5-year
survival of 80% versus 52% [8].
Besides histologic type, age of onset, and size of tumor, the
site of the tumor is highly important for staging and prognosis
of RMS [9]. Parameningeal rhabdomyosarcomas (PM-RMS)
comprise half of head andneckRMS cases, which also include
tumors located in the paranasal sinuses, nasal cavity, middle
ear, and the infratemporal and pterygopalatine fossae [8].
Most PM-RMS are of the embryonal type, whereas those with
alveolar features show a worse prognosis [10]. Patients with
parameningeal eRMS had a 4-year failure-free survival rate
of 68% on the most recent Children’s Oncology Group study
compared to 74% for similar eRMS with primary tumors at
other sites [11]. The poorer prognosis of PM-RMS is mainly
due to inaccessibility of the site and difficulty in achieving
negative surgical margins [12]. Local recurrence is the most
common form of relapse, and poor prognostic features
include intracranial spread and meningeal involvement [10].
In genetically engineered mice, extra-axial eRMS and
aRMS of the head and neck have been generated expressing
the Pax3:Foxo1 fusion gene and cooperating mutations [13–
15]. Adult pleomorphic rhabdomyosarcomas have also been
shown to develop spontaneously in aging A/J mice [16] or
with expression of oncogenic KRAS [6, 7]. Constitutive acti-
vation of the Hedgehog pathway in the adipocyte lineage of
mice has been associatedwith the formation of head and neck
tumors resembling eRMS [17]. However, preclinical models
of parameningeal eRMS tumors are still lacking. Xenograft
models of cancer can reflect the heterogeneity of human
tumors and create a stromal and vascular milieu not present
in cell lines. Preservation of these relationships can more
accurately mimic the behavior of human tumors, particularly
in their responses to treatment.While immunocompromised
test animals and subcutaneous implantation do not precisely
mimic the environment within the human body, it is the
nearest approximation available for research.
The rarity of PM-RMS and the clinically inaccessible site
have made collection of biopsy tissue for xenografting diffi-
cult. Here we present an invaluable PDXmodel, the first such
parameningeal eRMS preclinical model, for exploring the
biology and preclinical therapeutic avenues in parameningeal
RMS, created from tissue obtained at autopsy.
2. Case Presentation
A 14-year-old girl presented with a history of several weeks of
persistent headache, hoarse voice, and 20 lb weight loss with
tongue deviation on exam. A brain MRI scan showed a 1 ×
2 cm enhancing right-sided skull based mass that was invad-
ing the hypoglossal nerve canal (Figure 1(a)). Biopsy of the
mass showed poorly differentiated tumor with round to spin-
dled cells in amyxoid background (Figure 1(b)). An extensive
immunohistochemical panel including positive desmin and
myogenin stains was consistent with rhabdomyosarcoma
and cytogenetic testing was negative for (2; 13) and (1; 13)
translocations, which would be more consistent with alveolar
rhabdomyosarcoma. No anaplastic features were noted and
the tumor was diagnosed as embryonal rhabdomyosarcoma.
The tumor was not amenable to complete surgical resection,
and thus the patient was diagnosed with IRS Stage 2,
Group III eRMS. The patient received standard chemother-
apy with vincristine, actinomycin-D, and cyclophosphamide.
Local radiation therapy (RT) was initiated immediately for
symptomatic treatment and 50.4Gy RT to the local tumor
produced slow improvement in the vocal cord paralysis and
resolution of the tongue deviation.
Approximately 6 months after beginning chemotherapy
and 4 months after the completion of RT, the patient devel-
oped lower extremity weakness, gait disturbance, inconti-
nence, and headaches. Imaging revealed new diffuse lep-
tomeningeal metastases involving the entire brain and spine.
A ventriculoperitoneal shunt was placed, and, to address
symptoms of lower extremity weakness and incontinence, the
patient emergently received 30Gy palliative RT to her lower
thoracic spine. Shortly after completing RT, she developed
difficulty in breathing, seizures, and altered mental status.
With ongoing respiratory failure and neurologic deteriora-
tion, the family and medical team decided to transition the
patient to comfort care only. The patient died shortly after
extubation and permission to perform a complete autopsy
was given by the family. The study was conducted with
appropriate approval by the Institutional Review Board.
The autopsy was performed approximately 28 hours
after death. Examination revealed numerous fleshy masses
ranging from 1 to 6 cm involving the cerebrum (left frontal
and occipital cortex and underlying white matter, cingulate
gyrus bilaterally, genu of corpus callosum, left basal ganglia,
hypothalamus and left thalamus, right hippocampus, and
optic chiasm), cerebellum, and brainstem as well as the
leptomeninges.Metastatic tumorwas harvested sterilely from
several brain sites and placed immediately in RPMI solution
with sections fixed in 10% formalin for histology from the
same anatomic sites. Histology showed poorly differentiated
neoplasm with round to elongated spindled cells in a myxoid
background, highly similar to those seen in the previous
biopsy (Figure 1(c)).
3. Materials and Methods
3.1. PDX Model Creation. NSG (NOD.Cg-Prkdcscid
IL2rgtm1Wjl/SzJ) mice were obtained from The Jackson
Laboratory. These highly immune deficient mice have no
mature T or B lymphocytes or functional natural killer cells
and also have decreased cytokine signaling, rendering them
excellent subjects for human tissue engraftment. All studies
were done with the approval of The Jackson Laboratory
Institutional Animal Care and Use Committee. Tumor pie-
ces taken directly from the patient (50–125mm3) were
implanted subcutaneously into the rear flanks of recipient
female NSG mice using a trocar. Tumors were allowed to
grow to approximately 1000mm3 when the tumors were
collected and dissected into approximately 50mm3 frag-
ments. The fragments were serially passaged in NSG mice to
create cohorts ofmice for drug-testing purposes. Tomaintain
models and minimize genetic drift, fragments from the P0
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Figure 1: Radiographic imaging and comparative histology of human and PDX tumors: (a) 1 cm × 2 cm enhancing right-sided skull based
mass that was invading the hypoglossal nerve canal. (b) H&E slide, 400x of brain biopsy showing sheets of elongated spindled cells with
eosinophilic cytoplasm and amyxoid background, consistent with embryonal rhabdomyosarcoma. AnH&E slide, 400x from the frontal lobe
at autopsy (c), and a section of mouse xenograft, 200x (d), show highly similar morphologic features.
and P1 passages were frozen in 10% DMSO. These fragments
are used to generate low passage number cohorts of tumor
bearing mice as needed for study. PDX efficacy studies do
not go beyond passage 6.
3.2. Genomics. Gene expression analysis was performed with
the human exon 1.0 ST array (Affymetrix, Santa Clara, CA).
Only the initial passaged tumor (P0) was characterized for
gene expression because the patient sample could not be
collected quickly enough to ensure data quality. PDX gene
expression microarrays were processed in the R statistical
programming environment [18]. First, arrays were loaded
and grouped into probe sets with the BrainArray version 17
CDF [19] and Ensembl human gene annotations (annotation
version 70 using the human assembly GRCh37). Individ-
ual probe intensities were quantile normalized, and log-
transformed, but no background correction was performed.
Summarized expression intensities were generated with
the probe-level model as implemented by the AffyPLM R
package [20], fitting a simple model of the logarithmic
intensity for each probe as the sum of a sample effect, a probe
effect, and a residual term, with the sample effect represent-
ing the summarized intensity of the entire transcript/gene.
Mouse contamination effects on the arrays were assessed by
hybridization of NSGmouse skin samples on triplicate arrays
for the HuGene-1.0-st arrays.
Copy number variation for the patient tumor and the P0
PDX tumor were analyzed with the genome-wide human
6.0 SNP array (Affymetrix).Thewhole-genome allele-specific
copy number profiles, fraction of aberrant cells, and tumor
ploidy were estimated using ASCAT 2.2 [21, 22]. The input
data for ASCAT was generated from the CEL files using
the PennCNV-Affy package [23] which extracts the Log R
Ratios (LRR) andB-Allele Frequency (BAF) and performs the
GC correction. Ensemble genes (human genome annotation
version 70) were then annotated with the segmented copy
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number of the major (CNVa) and minor (CNVb) alleles.
Total copy number was computed by adding the values for
the major and minor alleles. A segment was defined as loss
of heterozygosity (LOH) if the major allele frequency was
greater than 0.5 and the minor allele was less than 0.1.
TruSeq Amplicon Cancer Panel. Using the Illumina proto-
col, mutation hotspots from forty-eight (48) cancer-related
genes were amplified and sequenced on the Illumina MiSeq
sequencer. The TruSeq data were analyzed using a bioin-
formatics analysis pipeline developed at Jackson Laboratory.
Briefly, sequencing reads generated by the platform were
initially assessed for mouse contamination using Xenome
v1.0.0 [24]. The human specific reads were further sub-
jected to quality control using NGSQCtoolkit v2.3 [25] and
reads with base quality greater than 30 over 70% of bases
were used in downstream analysis. High quality reads were
mapped to human genome (Hg19) using BWA [26]. The
resulting alignment was sorted by coordinates and fur-
ther converted to binary alignment format by Picard tools
(http://picard.sourceforge.net/). Subsequently, the IndelRe-
aligner and BaseRecalibrator modules in the Genome Anal-
ysis tool kit (GATK) were used to preprocess the alignments
[27, 28]. The realigned and recalibrated BAM file was used
as an input to GATK-UnifiedGenotyper and the variant calls
were restricted to the target region (Agilent sureSelect v4),
soft filtered with read depth less than 140. Finally, Pindel [29]
was used to identifymicrodeletions and all variantswith allele
frequency greater than 5% were reported.
3.3. Fluorescence In Situ Hybridization (FISH). FISHwas per-
formed with formalin-fixed paraffin embedded (FFPE) tissue
sections (4 𝜇M, cut from the tissue block PCB-00082PT)
using the StandardOperational Procedures (SOP) established
at the CLIA-certified Clinical Cytogenetics Laboratory at the
Jackson Laboratory for Genomic Medicine. The FFPE slides
were baked at 60∘C overnight and then deparaffinized with
xylene at room temperature for three times, 15 minutes each
time. The slides were dehydrated with 100% ethanol at room
temperature for 2 minutes and air-dried for approximately
15 minutes. The slides were treated with tissue pretreatment
and digestion kits according to the instructions provided by
the manufacturer (CytoCell). After digestion, the slides were
dehydrated with 70%, 90%, and 100% ethanol, respectively, at
room temperature for 2 minutes each, followed by air drying.
For denaturation and hybridization, the slides were placed
face-down onto a clean H&E slide and the unstained tissue
section on paraffin slide was aligned with the corresponding
tumor tissue area on theH&E slide. Using a diamond pen, the
target tumor area was marked on the slide to be processed for
FISH. 10 𝜇L of PAX3Breakapart probeswas applied (Cytocell,
LPS 012) and of PAX7 Breakapart probes (Cytocell, LPS 013)
onto two separate marked areas, respectively, and the area
was covered with a 22 × 22mm2 glass cover slip. The area
was sealed with rubber cement and the probes and slide were
codenatured on the Hybrite at 94∘C for 3 minutes. The slide
was placed in a humidified chamber and incubated at the
37∘C incubator for 48 hours. For posthybridization wash, the
slides were immersed in 0.5X SSC at 72∘C for 5 minutes.They
were washed 3 times in 1XPBS with 0.025%Tween 20 at room
temperature, 2 minutes each time. 10 𝜇L of DAPI was applied
to the marked area and it was covered with a 22 × 22mm2
glass cover slip. The edges of the glass cover slip were sealed
with nail polish to prevent slides from drying. In this study,
we also performed interphase FISH with a normal human
control cell line (GM12878) as a control test. The FISH slides
were analyzed using the Leica GSL120 image scanner system.
3.4. Efficacy Evaluation in Tumor Bearing Mice. Because
the patient’s tumor sample harbored an ALK mutation,
the potent, FDA-approved kinase inhibitor lestaurtinib was
chosen for preclinical studies. NSG mice with PDX tumors
at passage #2 and an average size of 250∼300mm3 were
randomized into vehicle control and the lestaurtinib (LC
Laboratories, Woburn, MA) treatment groups. Lestaurtinib
was prepared in 40% polyethylene glycol 100 (SpectrumNew
Brunswick, NJ), 10% povidone (ISP), and 2% benzyl alcohol
(Spectrum,) as previously described [30]. A total of nine
doses were given subcutaneously every 2 to 3 days over
a 3-week dosing period at 10mg/kg. Tumor volumes were
measured with a digital caliper 3 times weekly and calculated
using the formula: 0.5 × length ×width2 (mm3). Bodyweight,
hair coat, and activity were monitored 3 times a week and
animal welfare was checked daily. Animals were euthanized
when tumors reached a 2,000mm3 tumor endpoint. The
experiment was carried out twice. For the first experiment,
the vehicle group enrolled 7 mice and the lestaurtinib group
6 mice. The second experiment had 6 mice in both groups.
3.5. Statistical Analysis. Tumor volumes with standard error
were plotted. The curves were truncated when the number
of animals currently on study in particular cohorts decreased
to below 50% of the starting animal number for that cohort.
The tumor growth delay (TGD) method was used to analyze
drug treatment effects on time to tumor endpoint (TTE) for
the therapeutic dosing regimen [11]. Statistical significance
for median TTE values for treatment comparisons was
determined by the Log-rank test with a 95% confidence value
for two-tailed statistical analyses.
4. Results and Discussion
Five tumor fragments directly from the patient (50–125mm3)
were implanted into 5 recipient NSG mice to develop patient
derived xenograftmodels.Within 4months of tumor implan-
tation, all five mice developed tumors with approximately
1000mm3 volume. Histology was analyzed on all xenografts
and showed highly similar features to both the patient’s prior
premortem biopsy and autopsy specimens (Figure 1(d)). Ki-
67 immunohistochemical staining was performed to confirm
that human cells were proliferating within xenograft samples.
This model and associated data are publicly available and
represented in the JAX tumor model repository as PDX
model TM00360 [31].
Copy number variation was only assessed for the patient
tumor as the P0 PDX tumor failed quality control. Several
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Figure 2: Preclinical testing of lestaurtinib in a parameningeal PDX. (a, b) Kaplan-Meier analysis of PDX mice from two different treatment
cohorts.
regions of chromosomal amplification and deletion were
observed consistent with previous analyses of rhabdomyosar-
comas including gains in chromosomes 2, 8, 11, 12, and
20 [32]. Additionally, gains in chromosomes 5 and 19 were
observed. Losses were observed for chromosomes 2, 9, 10, and
11. Genes in the amplified regions included several frequently
amplified in soft tissue tumors: CDK4, MDM2, GLI4, and
MYC [33].
TruSeq cancer panel targeted amplicon sequencing in
both patient and P0 PDX tumor samples revealed an ALK
R1181C mutation and no other mutations in the 48 gene
panel including the NRAS, KRAS, HRAS, PIK3CA, CTNNB1,
and FBXW7 genes. The BCOR and FGFR4 genes were not
analyzed as they are not included in the TruSeq cancer panel.
FISH assay revealed no break-apart involving PAX3 or PAX7.
All mice equally tolerated the treatments with body
weights and clinical observations remaining stable for both
the vehicle and lestaurtinib treated mice. Tumors grew
progressively for both treatments as indicated bymean tumor
volumes over time. There was no statistical significance in
tumor growth between vehicle and lestaurtinib treatment
groups and the Kaplan-Meier survival curves did not dif-
fer significantly between vehicle and lestaurtinib treatment
groups (𝑝 > 0.05; Figure 2).
Chemotherapy is a mainstay of treatment for rhab-
domyosarcoma, particularly in cases such as our patient
when surgical resection is not feasible [34]. Monsma et al.
previously utilized a PDX model of alveolar rhabdomyosar-
coma, first identifying potential therapies by gene expression
profiling and then testing the efficacy of agents in vivo [35].
This approach is similar to the one taken in our study. Prior
mouse models of eRMS have shown varied pathways to
tumorigenesis with individual pathways correlated to specific
sites, suggesting that generation of site specific xenografts
could lend insight into treatment of rare variants such as PM-
RMS [36].
5. Conclusions
To our knowledge, this is the first patient-derived xenograft
for parameningeal rhabdomyosarcoma. We and others have
previously described the importance of research autopsy [37,
38]. This patient succumbed to fulminant eRMS with mass
effect after completing radiation and while still receiving
multiagent chemotherapy. The ability to obtain treatment
resistant eRMS tumor tissue at autopsy and generate PDX
is critical to our ability to understand the mechanisms of
resistance and to evaluate the impact of novel therapies
directed at identified targets. It is of particular interest that
while this tumor did demonstrate an ALK R1181C mutation,
lestaurtinib (which has a 71 nMKd forALK) still had no effect
[39]. It is possible that this mutation may not drive response
to therapy or that most recurrent cancers will not respond to
single agent treatment. While our study did not demonstrate
response of the xenograft tumors to a pan-kinase inhibitor,
generation of the PDX from autopsy tissue provides a tool for
identification of potential novel targeted therapies, as well as
treatments which might target lestaurtinib resistant tumors
in humans.
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